Please login to the form below

Not currently logged in
Email:
Password:

S-A in informal talks to acquire Genzyme

French drugmaker sanofi-aventis has approached Genzyme regarding a potential acquisition, according to a "reliable" source

French drugmaker sanofi-aventis (S-A) has approached Genzyme regarding a potential acquisition, according to a "reliable" source.

It is thought that S-A started informal talks with Genzyme, the largest maker of medicines for genetic diseases, about two weeks ago. The talks remain at an early stage and issues such as price and management have yet to be discussed.

Acquiring Genzyme would help S-A expand in biotechnology. Earlier this month, sources suggested S-A was planning an acquisition in the US that may be worth $20bn or more, but declined to be specific.

At the time, analysts cited Genzyme as a potential target for a takeover as well as Allegan and Biogen Idec.

Genzyme's current market capitalisation is close to $14bn.

Shares in the biotech firm climbed 21 per cent on the news of the talks, marking the largest stock price increase for Genzyme in more than a decade.

26th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics